WHO ICTRP trial
A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in…
EUCTR2006-004822-97-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2006-004822-97-GB |
|---|---|
| Public title | A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - Combination Infliximab and Sorafenib in RCC |
| Scientific title | A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - Combination Infliximab and Sorafenib in RCC |
| Primary sponsor | The Royal Marsden NHSF Trust |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United Kingdom |
| Conditions | Metastatic Renal Cell Carcinoma (RCC) MedDRA version: 8.1 Level: HLT Classification code 10038408 Term: Renal cell carcinomas |
| Interventions | Trade Name: Remicade Pharmaceutical Form: Powder for solution for infusion Trade Name: Nexavar Pharmaceutical Form: Film-coated tablet |
| Registration date | Aug 5, 2009 |
| Target size | 51 |
| Secondary IDs | EU-RD-001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: